Innovative monitoring system helps to reduce risk of infection, ulceration and amputation caused by diabetes

With the help of ANT+ wireless technology, diabetics will soon have access to a revolutionized pressure array monitoring solution that alerts the patient of critical conditions. The SurroSense Rx, developed by Orpyx Medical Technologies, is a highly-advanced yet extremely practical pressure-sensing insole that tells the user when damage is being done to the feet. The product is designed to mitigate foot complications experienced by diabetics.

“One of the main problems with diabetic peripheral neuropathy is that people are typically unaware of when pressure thresholds are being abused,” stated Dr. Breanne Everett, CEO of Orpyx Medical Technologies. “The result is tissue damage and infection, leading to ulceration and often amputation.  By alerting people in time, we hope to avoid much of this."

The SurroSense Rx collects pressure data from the foot and wirelessly sends that information to the user’s ANT+ enabled wristwatch or Smartphone application. The raw force data is analyzed and specialized software then converts the data into a risk profile. The risk profile is displayed on the user’s device and sends an alert when dangerous amounts of pressure are being applied. The user can then modify their behavior to avoid the devastating complications that may occur as a result. The device is updated with new information every 30 seconds and the low-power capability of ANT+ technology offers reliable data as well as a long and efficient battery life. 

Over 346 million people around the world are affected by diabetes and that number is increasing rapidly. The SurroSense Rx is the first device of its kind and it is expected to be released in early 2013 through a controlled launch with select clinics in the US.

For more information on the SurroSense Rx or Orpyx Medical Technologies, visit www.orpyx.com.

< Back to News